Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 4 2Phase 3 2Phase EARLY_PHASE1 1Phase 2/3 1Phase 2 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1ACTH-Secreting Pituitary Adenoma 1

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Completed × Cabergoline × Clear all
NCT03271918 2017-09-07

Cabergoline in Nonfunctioning Pituitary Adenomas

University of Sao Paulo General Hospital

Phase 3 Completed
140 enrolled
Endocrine

Pituitary Neoplasms

NCT00889525 2009-04-29

Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor

Seth Gordhandas Sunderdas Medical College

Phase 3 Completed
Endocrine

Pituitary ACTH Hypersecretion, ACTH-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡